DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients

Journal of Medical Genetics

Volumn 45, Issue 12, 2008, Pages 808-812

  Castaldo, I ^a   Pinelli, M ^a   Monticelli, A ^a,b   Acquaviva, F ^a   Giacchetti, M ^a   Filla, A ^a   Sacchetti, S ^c   Keller, S ^a,c   Avvedimento, V E ^a   Chiariotti, L ^a,c   Cocozza, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; DNA; FRATAXIN; GUANOSINE;

ADULT; ARTICLE; BINDING SITE; CHILD; CONTROLLED STUDY; CPG ISLAND; DNA FLANKING REGION; DNA METHYLATION; FRIEDREICH ATAXIA; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PYROSEQUENCING; QUANTITATIVE ANALYSIS; TRINUCLEOTIDE REPEAT;

ADOLESCENT; AGE OF ONSET; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DNA; DNA METHYLATION; FRIEDREICH ATAXIA; HUMANS; INTRONS; IRON-BINDING PROTEINS; MOLECULAR SEQUENCE DATA; TRINUCLEOTIDE REPEAT EXPANSION; YOUNG ADULT;

EID: 57349086192     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2008.058594     Document Type: Article

References (26)

1. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620.
2. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, Cocozza S. The relationship between trinucleotite (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996;59:554-60.
3. De Michele G, Perrone F, Filla A, Mirante E, Giordano M, De Placido S, Campanella G. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients. Neurology 1996; 47:1260-4.
4. Voncken M, Ioannou P, Delatycki MB. Friedreich's ataxia - update on pathogenesis and possible therapies. Neurogenetics 2004; 5:1-8.
5. Bidichandani SJ, Delatycki MB, Ashizawa T. http://www.geneclinics.org/.
6. Campuzano V, Montermini L, Molto MD Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Cañizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-7.
7. Babcock M, De Silva D, Oaks R. Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997;276:1709-12.
8. Koutnikova H, Campuzano V, Foury F. Dollé P, Cazzalini O, Koenig M. Studies of human, mouse and yeast homologoues indicate a mitochondrial function for frataxin. Nat Genet 1997; 16:345-51.
9. Delatycki MB, Camakaris J, Brooks H, Evans-Whipp T, Thorburn DR, Williamson R, Forrest SM. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neurol 1999; 45:673-5.
10. Bradley J, Blake J, Chamberlain S, Thomas PK, Cooper JM, Schapira AHA. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 2000;9:275-82.
11. Rotig A, Lonlay PD, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P. Aconitase and mitochondrial iron-sulfur protein deficiency in Friedreich ataxia. Nat Genet 1997;17:215-17.
12. Patel PI, Isaya G. Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency. Am J Hum Genet 2001; 69:15-24.
13. Martens JH, O'Sullivan RJ, Braunschweig U, Opravil S, Radolf M, Steinlein P, Jenuwein T. The profile of repeat-associated histone lysine methylation states in the mouse epigenome. EMBO J 2005; 24:800-12.
14. Greene E, Mahishi L, Entezam L, Kumari D, Usdin K. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Research 2007; 35:3383-90.
15. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning. A laboratory manual. Cold Spring Harbor: Cold Spring Harbour Laboratory, 1982.
16. Ozanne SE, Constancia M. Mechanisms of disease: the developmental origins of disease and the role of the epigenotype. Nat Clin Pract Endocrinol Metab 2007;3:539-46.
17. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
18. Waggoner D. Mechanisms of disease: epigeness. Semin Pediatr Neurol 2007;14:7-14.
19. Steinbach P, Glaser D, Vogel W, Wolf M, Schwemmle S. The DMPK gene of severely affected myotonic dystrophy patients is hypermethylated proximal to the largely expanded CTG repeat. Am J Hum Genet 1998;62:278-85.
20. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, Warren ST. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1992;1:397-400.
21. Saul RA, Tarleton JC. FMR1-related disorders. http://www.geneclinics.org/.
22. Herman D, Jenssen K, Bumett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2:551-8.
23. Al-Mahdawi S, Pinto R M, Ismail O, Varshney D, Lymperi S, Sandi C, Trabzuni D, Pook M. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 2008;17:735-46.
24. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 2003;422:909-13.
25. Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M, Monticelli A, Criscuolo C, Filla A, Cocozza S. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry 2004;75:1061-3.
26. Di Prospero NA, Fischbeck KH. Therapeutics development for triplet repeat expansion diseases. Nat Rev Genet 2005;6:756-65.